Your browser doesn't support javascript.
loading
CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph.
Hensen, Luca; Illing, Patricia T; Bridie Clemens, E; Nguyen, Thi H O; Koutsakos, Marios; van de Sandt, Carolien E; Mifsud, Nicole A; Nguyen, Andrea T; Szeto, Christopher; Chua, Brendon Y; Halim, Hanim; Rizzetto, Simone; Luciani, Fabio; Loh, Liyen; Grant, Emma J; Saunders, Phillipa M; Brooks, Andrew G; Rockman, Steve; Kotsimbos, Tom C; Cheng, Allen C; Richards, Michael; Westall, Glen P; Wakim, Linda M; Loudovaris, Thomas; Mannering, Stuart I; Elliott, Michael; Tangye, Stuart G; Jackson, David C; Flanagan, Katie L; Rossjohn, Jamie; Gras, Stephanie; Davies, Jane; Miller, Adrian; Tong, Steven Y C; Purcell, Anthony W; Kedzierska, Katherine.
Afiliação
  • Hensen L; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Illing PT; Department of Biochemistry and Molecular Biology & Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Bridie Clemens E; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Nguyen THO; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Koutsakos M; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • van de Sandt CE; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Mifsud NA; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Nguyen AT; Department of Biochemistry and Molecular Biology & Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Szeto C; Department of Biochemistry and Molecular Biology & Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Chua BY; Department of Biochemistry and Molecular Biology & Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Halim H; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Rizzetto S; Department of Biochemistry and Molecular Biology & Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Luciani F; School of Medical Sciences and The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
  • Loh L; School of Medical Sciences and The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.
  • Grant EJ; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Saunders PM; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Brooks AG; Department of Biochemistry and Molecular Biology & Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Rockman S; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Kotsimbos TC; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Cheng AC; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Richards M; Seqirus, Parkville, VIC, Australia.
  • Westall GP; Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia.
  • Wakim LM; Department of Medicine, Monash University, Central Clinical School, The Alfred Hospital, Melbourne, VIC, Australia.
  • Loudovaris T; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Mannering SI; Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, VIC, Australia.
  • Elliott M; Victorian Infectious Diseases Service, The Royal Melbourne Hospital, and Doherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Tangye SG; Lung Transplant Unit, Alfred Hospital, Melbourne, VIC, Australia.
  • Jackson DC; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Flanagan KL; Immunology and Diabetes Unit, St Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
  • Rossjohn J; Immunology and Diabetes Unit, St Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
  • Gras S; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
  • Davies J; Chris O'Brien Lifehouse Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
  • Miller A; Immunology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
  • Tong SYC; St. Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
  • Purcell AW; Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia.
  • Kedzierska K; Tasmanian Vaccine Trial Centre, Launceston General Hospital, Launceston, TAS, Australia.
Nat Commun ; 12(1): 2931, 2021 05 18.
Article em En | MEDLINE | ID: mdl-34006841
Indigenous people worldwide are at high risk of developing severe influenza disease. HLA-A*24:02 allele, highly prevalent in Indigenous populations, is associated with influenza-induced mortality, although the basis for this association is unclear. Here, we define CD8+ T-cell immune landscapes against influenza A (IAV) and B (IBV) viruses in HLA-A*24:02-expressing Indigenous and non-Indigenous individuals, human tissues, influenza-infected patients and HLA-A*24:02-transgenic mice. We identify immunodominant protective CD8+ T-cell epitopes, one towards IAV and six towards IBV, with A24/PB2550-558-specific CD8+ T cells being cross-reactive between IAV and IBV. Memory CD8+ T cells towards these specificities are present in blood (CD27+CD45RA- phenotype) and tissues (CD103+CD69+ phenotype) of healthy individuals, and effector CD27-CD45RA-PD-1+CD38+CD8+ T cells in IAV/IBV patients. Our data show influenza-specific CD8+ T-cell responses in Indigenous Australians, and advocate for T-cell-mediated vaccines that target and boost the breadth of IAV/IBV-specific CD8+ T cells to protect high-risk HLA-A*24:02-expressing Indigenous and non-Indigenous populations from severe influenza disease.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Epitopos de Linfócito T / Antígeno HLA-A24 / Povos Indígenas Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T CD8-Positivos / Epitopos de Linfócito T / Antígeno HLA-A24 / Povos Indígenas Idioma: En Ano de publicação: 2021 Tipo de documento: Article